Delivery Order SPE2DB20D2104-SPE2DB25FMZXC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,583.57 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count units) on August 14, 2025, with completion scheduled for August 15, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,866.48 to AmerisourceBergen Drug Corp for 30 tablets of Entecavir 0.5 mg, an antiviral medication commonly used to treat chronic hepatitis B. The contract, which is not set-aside, was awarded on September 2, 2025, with an ultimate completion date of September 3, 2025, utilizing firm fixed pricing. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,202.28 to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Entecavir 0.5 mg tablets (30-count package) with a ceiling value of $1,337.46. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was not designated as a set-aside contract, indicating it was competitively awarded through open...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Entecavir 0.5 mg tablets in quantities of 30 units. This contract, valued at $2,631.62, represents a firm fixed price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is...
- The Defense Logistics Agency awarded a $1,996.61 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Entecavir 0.5 mg tablets (30-count units). This is a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, consistent with AmerisourceBergen's typical federal procurement profile....
- This is a $3,973.50 firm fixed-price delivery order contract awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., by the Defense Logistics Agency (DLA). The contract is for the delivery of Entecavir 0.5 mg tablets, a medication used to treat chronic hepatitis B. The contract has a completion date of May 3, 2023 and was awarded on May 2, 2023. This contract is not designated as a set-aside and was awarded through full and open competition. Amerisourcebergen Drug Corp holds a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Entecavir 0.5 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $1,142.56. The order was competitively awarded without set-aside restrictions and is scheduled for completion by August 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform fulfillment from its corporate office location. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Entecavir 0.5 mg tablets (30-count packaging) with a ceiling value of $1,650.08 under a firm fixed price contract type. The award was made on August 18, 2025, with an ultimate completion date of August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation. This delivery...
- This is a delivery order awarded by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Entecavir 0.5 mg tablets in 30-count packages, with a firm fixed price of $1,409.13 and a completion date of June 25, 2025. The contract is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMZXCDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,296.38 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Entecavir 0.5 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 10, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Entecavir is an antiviral medication primarily used in the treatment of chronic hepatitis B, representing a critical pharmaceutical commodity within the DLA Medical Supply Chain's broader healthcare procurement mission. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen Drug Corp serves as a major supplier of medications and medical supplies to military healthcare systems, the Defense Health Agency, and other federal health programs worldwide. The company's substantial contract portfolio demonstrates its capability to fulfill federal medical procurement requirements through competitive selection and firm fixed-price delivery mechanisms across diverse therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/9/25 |